The latest update is out from Sonnet BioTherapeutics Holdings (SONN).
The Company’s groundbreaking treatment for chemotherapy-induced peripheral neuropathy (CIPN), SON-080, has successfully passed Phase 1b and is advancing to Phase 2 trials. This innovative therapy utilizes a low dose of rhIL-6, mirroring the body’s natural healing response triggered by moderate exercise, to stimulate nerve regrowth and alleviate patients’ persistent pain. The initial safety results from the trials have been promising, with the most common side effects being manageable and transient, allowing the study to continue as planned with further results anticipated in the latter half of 2024.
See more data about SONN stock on TipRanks’ Stock Analysis page.
